Options
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
ISSN
1473-7167
1744-8379
Date Issued
2022
Author(s)
Carlos Balmaceda
Manuel A. Espinoza
Tomas Abbott
Type
Resource Types::text::journal::journal article
Cite this document
Balmaceda, C., Espinoza, M. A., Abbott, T., & Peters, A. (2022). Cost-effectiveness analysis: Fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Review of Pharmacoeconomics & Outcomes Research, 22(5), 743-751. https://doi.org/10.1080/14737167.2022.2044308
Subjects
cost-effectiveness analysis
;
chronic obstructive pulmonary disease
;
single inhaler triple therapy
;
quality-adjusted life years
;
chile
;
androstadienes
;
benzyl alcohols
;
bronchodilator agents
;
chile
;
chlorobenzenes
;
cost-benefit analysis
;
double-blind method
;
drug combinations
;
fluticasone
;
forced expiratory volume
;
humans
;
public health
;
pulmonary disease, chronic obstructive
;
quinuclidines
;
treatment outcome
;
fluticasone furoate plus umeclidinium plus vilanterol
;
fluticasone furoate plus vilanterol
;
fluticasone propionate plus salmeterol
;
tiotropium bromide
;
umeclidinium plus vilanterol
;
androstane derivative
;
benzyl alcohol derivative
;
bronchodilating agent
;
chlorobenzene
;
fluticasone
;
fluticasone furoate
;
quinuclidine derivative
;
umeclidinium
;
vilanterol
;
article
;
chronic obstructive lung disease
;
cohort analysis
;
cost effectiveness analysis
;
gross national product
;
human
;
public health
;
sensitivity analysis
;
treatment outcome
;
chile
;
chronic obstructive lung disease
;
cost benefit analysis
;
double blind procedure
;
drug combination
;
forced expiratory volume